Join BIOCYTOGEN at Sino-American Pharmaceutical Professionals Association (SAPA), Connecticut 2024
We’re thrilled to announce our participation as an exhibitor at the Sino-American Pharmaceutical Professionals Association (SAPA) Connecticut 2024 conference. Taking place on December 7th in New Haven, this prestigious event will gather top experts and innovators in the pharmaceutical field to exchange ideas, share insights, and advance new developments. Join us as we connect with leaders shaping the future of the industry!
What is the Sino-American Pharmaceutical Professionals Association (SAPA) 2024, Connecticut?
SAPA-CT serves as a vibrant community for professionals in Connecticut’s pharmaceutical and biotech sectors, encompassing members from local companies, research institutes, and universities. Its mission focuses on advancing pharmaceutical sciences and biotechnology in Connecticut, fostering collaborations between American and global life science industries, and supporting the career growth of industry professionals.
Through annual meetings, scientific symposiums, career development forums, and other signature events, SAPA-CT has become a vital force within the SAPA community. This year’s conference will highlight cutting-edge technology in drug discovery, the role of big data and AI in accelerating drug development, new trends in translational medicine, and a career development workshop, offering a dynamic platform for networking and growth.
Event Overview
Date: December 7th
Venue: Yale University
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the Sino-American Pharmaceutical Professionals Association (SAPA) 2024 in New Haven, Connecticut!
